The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC).
 
Tanya Jindal
No Relationships to Disclose
 
Li Zhang
Consulting or Advisory Role - Raydiant Oximetry
Travel, Accommodations, Expenses - Dendreon; Dendreon; Dendreon
 
Jonathan Chou
Stock and Other Ownership Interests - Array BioPharma (I); Atara Biotherapeutics (I); Bluebird Bio (I); Celgene (I); Exelixis (I)
Research Funding - Amgen Astellas BioPharma (Inst)
 
David Shui
No Relationships to Disclose
 
Sima P. Porten
Honoraria - photocure
Consulting or Advisory Role - Bristol-Myers Squibb; KDx Diagnostics; Photocure; Protara Therapeutics
Research Funding - Photocure (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Anthony C. Wong
No Relationships to Disclose
 
Emily Chan
No Relationships to Disclose
 
Bradley A. Stohr
No Relationships to Disclose
 
Ivan de Kouchkovsky
No Relationships to Disclose
 
Hala Borno
Employment - Collective Health (I)
Leadership - Collective Health (I)
Stock and Other Ownership Interests - Collective Health (I)
Honoraria - BMS; Dendreon
Consulting or Advisory Role - BMS; Dendreon
 
Rohit Bose
Travel, Accommodations, Expenses - Janssen Biotech
 
Daniel H Kwon
Stock and Other Ownership Interests - Invitae
 
Arpita Desai
Consulting or Advisory Role - Dendreon; Janssen Oncology
 
Franklin W. Huang
No Relationships to Disclose
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Eric Jay Small
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics; Teon Therapeutics
Honoraria - Janssen; Johnson and Johnson
Consulting or Advisory Role - Beigene; Fortis; Fortis; Janssen Oncology; Teon Therapeutics; Tolero Pharmaceuticals; Ultragenyx Pharmaceuticals
Research Funding - Janssen (Inst)
Travel, Accommodations, Expenses - Janssen
 
Lawrence Fong
Stock and Other Ownership Interests - Alector; Alector; Atreca; BioAtla; Bolt Biotherapeutics; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; TeneoBio; TeneoBio
Consulting or Advisory Role - Alector; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Dendreon; EMD Serono; Janssen Oncology; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; TeneoBio
Research Funding - Abbvie (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Terence W. Friedlander
Leadership - Med BioGene
Honoraria - AstraZeneca/MedImmune; EMD Serono; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Consulting or Advisory Role - Abbvie; Abbvie; AstraZeneca; Dava Oncology; Dendreon; EMD Serono; Janssen; Merck; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Janssen; Neon Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Genentech/Roche; Jounce Therapeutics
 
Vadim S Koshkin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte; Janssen Oncology; Nektar; Taiho Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen